Literature DB >> 1404155

Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma.

C A Feghali1, K L Bost, D W Boulware, L S Levy.   

Abstract

Fibroblasts were cultured from affected skin sites of patients with progressive systemic sclerosis (PSS), from unaffected skin sites of the same patients, and from a healthy donor. The concentration of interleukin 6 (IL-6) in culture medium conditioned by the growth of early passage cells was determined by radioimmunoassay and by quantitative bioassay. Results demonstrated that fibroblasts from affected PSS skin produce from 6 to 30-fold higher levels of biologically active IL-6 compared to unaffected and control cells. In contrast, serum IL-6 concentrations in 6 of 8 patients examined were not significantly different from healthy donors. Serum IL-6 levels were elevated 2 to 3-fold in 2 of 8 patients examined. Thus, the overproduction of IL-6 by affected scleroderma fibroblasts does not necessarily correlate with a systemic increase in IL-6, but may increase its concentration locally. In view of its biological activities, including stimulation of antibody production and T cell activation, the overproduction of IL-6 by PSS fibroblasts in the lesions may play a significant role in the pathogenesis of PSS and may profoundly influence the course of the disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1404155

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  43 in total

Review 1.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

2.  An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.

Authors:  Flavia V Castelino; Gretchen Bain; Veronica A Pace; Katharine E Black; Leaya George; Clemens K Probst; Lance Goulet; Robert Lafyatis; Andrew M Tager
Journal:  Arthritis Rheumatol       Date:  2016-12       Impact factor: 10.995

Review 3.  Incidence of hypertrophic scars among African Americans linked to vitamin D-3 metabolism?

Authors:  Gerald L Cooke; Anna Chien; Amy Brodsky; Raphael C Lee
Journal:  J Natl Med Assoc       Date:  2005-07       Impact factor: 1.798

4.  Serum interleukin-6 level in patients with systemic sclerosis: lack of correlation with aminoterminal propeptide of type III procollagen.

Authors:  E J Kucharz; G Jonderko; J Rubisz-Brzezinska; L Brzezinska-Wcisło
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

5.  The mighty fibroblast and its utility in scleroderma research.

Authors:  Sara M Garrett; DeAnna Baker Frost; Carol Feghali-Bostwick
Journal:  J Scleroderma Relat Disord       Date:  2017-05-19

6.  Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-gamma in vascular inflammation.

Authors:  Z Szekanecz; M R Shah; W H Pearce; A E Koch
Journal:  Agents Actions       Date:  1994-10

7.  Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers.

Authors:  C P Denton; X Shi-Wen; A Sutton; D J Abraham; C M Black; J D Pearson
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

8.  Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension.

Authors:  Yoshiaki Furuya; Toru Satoh; Masataka Kuwana
Journal:  Int J Rheumatol       Date:  2010-08-02

9.  The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

Authors:  Yoshihito Shima; Yusuke Kuwahara; Hiroyuki Murota; Shun Kitaba; Mari Kawai; Toru Hirano; Junsuke Arimitsu; Masashi Narazaki; Keisuke Hagihara; Atsushi Ogata; Ichiro Katayama; Ichiro Kawase; Tadamitsu Kishimoto; Toshio Tanaka
Journal:  Rheumatology (Oxford)       Date:  2010-09-05       Impact factor: 7.580

10.  Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis.

Authors:  J-Y Kim; S-K Kwok; K-H Hur; H-J Kim; N S Kim; S-A Yoo; W-U Kim; C-S Cho
Journal:  Clin Exp Immunol       Date:  2008-03-18       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.